Literature DB >> 3389342

Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma.

G H Albers1, G Fleuren, M J Escribano, M Nap.   

Abstract

This study describes the immunohistologic distribution of carcinoembryonic antigen (CEA) in 30 fetal pancreata, 5 normal adult pancreata, 11 cases of chronic pancreatitis without carcinoma, 16 cases of chronic pancreatitis with carcinoma, and 20 cases of primary pancreatic adenocarcinoma. The position of CEA-cross-reacting antigen, especially of nonspecific cross-reacting antigen (NCA), was also studied in the case of chronic pancreatitis and pancreatic adenocarcinoma. For this purpose, both monospecific antibodies to CEA and NCA, as well as cross-reacting antibodies, were used in an indirect immunoperoxidase technique. CEA reactivity could not be detected, neither during pancreatic development nor in chronic pancreatitis with or without associated adenocarcinoma. In 15 of 20 pancreatic adenocarcinomas, CEA positivity was found both with membranous and cytoplasmic localization. With the use of the cross-reacting antibodies, all cases of chronic pancreatitis and pancreatic adenocarcinomas showed positive staining of both ductal and tubular structures. Antibodies to NCA closely mimicked the results obtained with the cross-reacting antibodies both in pancreatitis and adenocarcinoma. From the authors' results it can be concluded that CEA is not a developmental antigen of the pancreas. Furthermore, NCA cross-activity of anti-CEA antibodies is an important reason of false positive reaction in chronic pancreatitis. Moreover, true CEA positivity in the pancreas appears to be restricted to adenocarcinoma of the exocrine pancreas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3389342     DOI: 10.1093/ajcp/90.1.17

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

1.  Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer.

Authors:  Hop S Tran Cao; Sharmeela Kaushal; Cristina A Metildi; Rhiana S Menen; Claudia Lee; Cynthia S Snyder; Karen Messer; Minya Pu; George A Luiken; Mark A Talamini; Robert M Hoffman; Michael Bouvet
Journal:  Hepatogastroenterology       Date:  2012-09

Review 2.  CAR T-cell therapy for pancreatic cancer.

Authors:  Carl J DeSelm; Zachary E Tano; Anna M Varghese; Prasad S Adusumilli
Journal:  J Surg Oncol       Date:  2017-03-27       Impact factor: 3.454

3.  Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.

Authors:  E Heyderman; S E Larkin; P J O'Donnell; A M Haines; P J Warren; A Northeast; A G Grant
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

4.  Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation.

Authors:  Christian Ilantzis; Luisa DeMarte; Robert A Screaton; Clifford P Stanners
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

Review 5.  Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.

Authors:  Vishal Jindal; Ena Arora; Muhammad Masab; Sorab Gupta
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

6.  Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer.

Authors:  Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet
Journal:  J Gastrointest Surg       Date:  2008-07-30       Impact factor: 3.452

Review 7.  Current status and future perspectives of fluorescence-guided surgery for cancer.

Authors:  Jonathan C DeLong; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2015-12-07       Impact factor: 4.512

Review 8.  Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?

Authors:  Toru Mizuguchi; Toshihiko Torigoe; Fukino Satomi; Hiroaki Shima; Goro Kutomi; Shigenori Ota; Masayuki Ishii; Hiroshi Hayashi; Sumiyo Asakura; Yoshihiko Hirohashi; Makoto Meguro; Yasutoshi Kimura; Toshihiko Nishidate; Kenji Okita; Masaho Ishino; Atsushi Miyamoto; Masamitsu Hatakenaka; Noriyuki Sato; Koichi Hirata
Journal:  Surg Today       Date:  2015-02-05       Impact factor: 2.540

9.  Targeting CEA in Pancreas Cancer Xenografts with a Mutated scFv-Fc Antibody Fragment.

Authors:  Mark D Girgis; Tove Olafsen; Vania Kenanova; Katelyn E McCabe; Anna M Wu; James S Tomlinson
Journal:  EJNMMI Res       Date:  2011-11-07       Impact factor: 3.138

10.  A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.

Authors:  Thomas F Gajewski; Hedy L Kindler; Daniel M Geynisman; Yuanyuan Zha; Rangesh Kunnavakkam; Mebea Aklilu; Daniel Vt Catenacci; Blase N Polite; Cara Rosenbaum; Azadeh Namakydoust; Theodore Karrison
Journal:  J Immunother Cancer       Date:  2013-06-27       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.